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The effectiveness of inhalation therapy, especially for a drug
dry powder formulation (DPI), is dependent on factors that are
related to the patient, the device and the characteristics of the
formulation.
The engineered drug particles theirselves are typically
highly cohesive and display poor aerosolization properties,
necessitating the addition of a coarse carrier particle to the
micronized drug.
Our aims were to develop mannitol-based carrier systems
containing aqueous and ethanolic solution during co-spray-
drying procedures and application of different types of
additives could help the DPI formulation of also watersoluble
and insoluble drug.
Mannitol (M), a hydrophilic carrier, was obtained from
Hungaropharma Budapest, Hungary; PVA3-88 is ordere from
ISPCustomer ServiceGmBH,Cologne,Germany; amino acid
such as L-leucine (LEU) is from Applichem, Germany.
Hydroxypropyl beta cyclodextrin as complex former and
permeability improving agent is from Cylolab Ltd (Budapest,
Hungary).
The procedure of spray-drying (spd) was from a aqueous(w)
and ethanolic solution (10% of EtOH and 90 % of water (mix))
of M, LEU with/without CD or PVA using a Büchi Mini
Dryer B-191. The amount of additives was determined
according to our preliminary work. The amount of CD was
calculated according its complex former ratio e.g. 1:1 2:1 4:1.
(Fig. 1 ).
The particle size distribution of themicrocomposites was also
estimated by laser diffraction (Malvern Mastersizer Scirocco
2000, Malvern Instruments Ltd., Worcestershire, UK). The
morphology of the microcomposites was examined by SEM
(Hitachi S4700,Hitachi Scientific Ltd., Tokyo, Japan).
Andersen Cascade Impactor (ACI) (Copley Scientific Ltd.,
Nottingham, UK) is used for measuring the mass distribution
of pharmaceutical aerosols via the aerodynamic diameter
using 60Lmin-1 flow rate. The products were filled into hard
gelatine capsules (size 3). The inhaler device applied was a
plasticRS01 (Plastiape, Italy).
XRPD was carried out in order to determine the crystalline
formand crystallinity of the producedmaterials. Sampleswere
measured with a Bruker D8 Advance diffractometer (Bruker
AXS GmbH, Karlsruhe, Germany). Thermoanalitical
measurements were also applied (Mettler Toledo, Stare
programW9,Mettler Inc. SwerzenbachSwitzerland)
In our present work three suitable ways were applied to
developed pulmonary drug delivery systems (PDDS) of
different drugs. During spray-drying procedure aqueous and
ethanolic solution of the excipients could be applied, which
help to solve or disperg the drug. If the drug is very poorly
soluble in water or ethanol/water mixture, the present of CD
can help by formation of inclusion complex. According to the
morphology, the size, size distribution and fine particle fraction
(FPF) calculation of the samples, they are applicable asPDDS
(Fig. 2).
Particle characterization
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omogenous distribution (Table 1). According to the
aerodynamicmeasurements the FPFare higher comparewith
the maketed products.The crystal morphology is a critical
parameter for DPI development, because the particle shape
affects the aerodynamic behaviour and thus lung deposition.
The effect of spray-drying procedure on the morphology of
particles was determinative. The spherical form of the
microcomposites could be advantageous for suitable
pulmonary depositions (Figs. 3-4).
Structural investigations
Evaluation of the structural analysis usingDSCandXRPD,we
can conclude that the raw M is crystalline and additives are
semi-crystalline/amorphous materials. The samples are
mainly crystalline, the degree of the crystallinity decreased
and because of the increased concentration of CD turned to
amorphous character. (Figs. 5-8).
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The particle sizes of the samples satisfied the pharmacopoeial
requirements, the average size was between 2.5- .5 μm
resulted h
Figure 2. Development-protocol Table 1. Size and Aerodynamic properties
Figure 8. XRPD patterns of the samples
containing cyclodextrins
Figure 4. Morphology of the products
Figure 7. XRPD patterns of the samples
containing mannitol
Figure 5. DSC curves of the samples
containing PVA
Figure 6. DSC curves of the samples
containing LEU
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Figure 1. Materials and preparation procedure
Co-spray-drying procedure:
Inlet temperature: 140 °C
Feed rate: 75 %
Apirator air: 600 L/min
Aspirator rate: 5 %
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Figure 3. Morphology of the products
Sample D 0.1 (µm) D 0.5 (µm) D 0.9 (µm)
FPF
(%)
M-w 1.38 2.91 4.63 81.45
M-mix 1.51 2.79 4.57 70.27
M-PVA-w 2.95 6.36 10.18 25.85
M-PVA-mix 2.41 4.72 9.49 38.91
M-LEU-w 2.27 4.05 8.32 72.33
M-LEU-mix 1.38 2.83 5.57 59.51
M-LEU-CD0.9 1.61 3.30 6.46 46.52
M-LEU-CD1.8 2.35 5.47 10.22 40.78
M-LEU-CD3.6 3..95 8.25 12.10 36.91
Sample M PVA LEU CD solvent
M-w 5 - - - water
M-mix 5 - - - mix
M-PVA-w 5 0.2 - - water
M-PVA-mix 5 0.2 - - mix
M-LEU-w 5 - 0.4 - water
M-LEU-mix 5 - 0.4 - mix
M-LEU-CD0.9 5 - 0.4 0.9 mix
M-LEU-CD1.8 5 - 0.4 1.8 mix
M-LEU-CD3.6 5 - 0.4 3.6 mix
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Mannitol-based Carrier Systems
Carrier: Mannitol
Solvent: Water
Additives: LEU or PVA
Carrier: Mannitol
Solvent: 90 %Water and
10% Ethanol
Additives: LEU or PVA
Carrier: Mannitol
Solvent: Water-Ethanol
Additives: LEU and CD
API could be dissolved
API could be suspended
API could be dissolved API could be dissolved
by form inclusion complex
